Earnings Snapshot: Novavax beats Q2 top and bottom line estimates; raises FY26 adjusted total revenue outlook

Both quarterly revenue and net income (top and bottom line) exceeded expectations, and the upward revision of the FY26 adjusted total revenue guidance is a positive signal of fundamental improvement. However, it is necessary to further confirm whether the financial momentum at the current stock price level ($7.70) will establish itself as a long-term trend.

Novavax's strong Q2 performance and the upward revision of its FY26 annual revenue guidance serve as a clear performance-based catalyst demonstrating improvement in its own business results.